BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28529638)

  • 1. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma.
    Lapa C; Herrmann K; Schirbel A; Hänscheid H; Lückerath K; Schottelius M; Kircher M; Werner RA; Schreder M; Samnick S; Kropf S; Knop S; Buck AK; Einsele H; Wester HJ; Kortüm KM
    Theranostics; 2017; 7(6):1589-1597. PubMed ID: 28529638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease.
    Herrmann K; Schottelius M; Lapa C; Osl T; Poschenrieder A; Hänscheid H; Lückerath K; Schreder M; Bluemel C; Knott M; Keller U; Schirbel A; Samnick S; Lassmann M; Kropf S; Buck AK; Einsele H; Wester HJ; Knop S
    J Nucl Med; 2016 Feb; 57(2):248-51. PubMed ID: 26564323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation.
    Maurer S; Herhaus P; Lippenmeyer R; Hänscheid H; Kircher M; Schirbel A; Maurer HC; Buck AK; Wester HJ; Einsele H; Grigoleit GU; Keller U; Lapa C
    J Nucl Med; 2019 Oct; 60(10):1399-1405. PubMed ID: 30850502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma.
    Lapa C; Hänscheid H; Kircher M; Schirbel A; Wunderlich G; Werner RA; Samnick S; Kotzerke J; Einsele H; Buck AK; Wester HJ; Grigoleit GU
    J Nucl Med; 2019 Jan; 60(1):60-64. PubMed ID: 29777009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma.
    Buck AK; Grigoleit GU; Kraus S; Schirbel A; Heinsch M; Dreher N; Higuchi T; Lapa C; Hänscheid H; Samnick S; Einsele H; Serfling SE; Werner RA
    J Nucl Med; 2023 Jan; 64(1):34-39. PubMed ID: 35738903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extramedullary Relapsed Multiple Myeloma Treatment With 177Lu-Labeled CXCR4 Endoradiotherapy and Dosimetric Results.
    Demirkol MO; Özkan A; Uçar B; Wester HJ; Ferhanoğlu B
    Clin Nucl Med; 2021 Aug; 46(8):656-658. PubMed ID: 34034308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [
    Lapa C; Schreder M; Schirbel A; Samnick S; Kortüm KM; Herrmann K; Kropf S; Einsele H; Buck AK; Wester HJ; Knop S; Lückerath K
    Theranostics; 2017; 7(1):205-212. PubMed ID: 28042328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors.
    Hartlapp I; Hartrampf PE; Serfling SE; Wild V; Weich A; Rasche L; Roth S; Rosenwald A; Mihatsch PW; Hendricks A; Wiegering A; Wiegering V; Hänscheid H; Schirbel A; Werner RA; Buck AK; Wester HJ; Einsele H; Kunzmann V; Lapa C; Kortüm KM
    J Nucl Med; 2023 Sep; 64(9):1424-1430. PubMed ID: 37348915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics.
    Habringer S; Lapa C; Herhaus P; Schottelius M; Istvanffy R; Steiger K; Slotta-Huspenina J; Schirbel A; Hänscheid H; Kircher S; Buck AK; Götze K; Vick B; Jeremias I; Schwaiger M; Peschel C; Oostendorp R; Wester HJ; Grigoleit GU; Keller U
    Theranostics; 2018; 8(2):369-383. PubMed ID: 29290814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
    Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
    Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
    Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
    Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.
    Hicks C; Isaacs A; Wong R; Chong BH
    Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear Medicine Application of Pentixafor/Pentixather Targeting CXCR4 for Imaging and Therapy in Related Disease.
    Chen Z; Xue Q; Yao S
    Mini Rev Med Chem; 2023; 23(7):787-803. PubMed ID: 36529918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
    Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Richter J; Skarbnik AP; Pecora A; Siegel DS
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2165-2171. PubMed ID: 27590107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
    Zannetti BA; Tacchetti P; Pantani L; Gamberi B; Tosi P; Rocchi S; Cellini C; Ronconi S; Pezzi A; Mancuso K; Rizzello I; Caratozzolo I; Martello M; Dozza L; Cavo M; Zamagni E
    Ann Hematol; 2017 Dec; 96(12):2071-2078. PubMed ID: 29063955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma.
    Peled A; Abraham M; Avivi I; Rowe JM; Beider K; Wald H; Tiomkin L; Ribakovsky L; Riback Y; Ramati Y; Aviel S; Galun E; Shaw HL; Eizenberg O; Hardan I; Shimoni A; Nagler A
    Clin Cancer Res; 2014 Jan; 20(2):469-79. PubMed ID: 24246358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.